The Effect of Naproxen on Fever in Patients with Advanced Gynecologic Malignancies

Katherine Economos, Joseph A. Lucci, Barbara Richardson, Roberto Yazigi, David Scott Miller

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The antipyretic action of naproxen has been reported as sufficiently selective for neoplasm-related fever such that the use of this agent has been recommended to distinguish neoplastic from infectious fever. The antipyretic effect of naproxen was evaluated in gynecologic oncology patients with advanced pelvic malignancies and fever without obvious source of infection (suspected neoplastic fever). Naproxen (250 mg orally every 8 hr) was given to 12 patients with (i) a daily temperature greater than 38.3°C, (ii) fever for at least 3 days, (iii) no evidence of infection on physical exam, (iv) negative results of blood and urine cultures, and (v) a chest roentgenogram negative for pneumonia. Ten of the 12 patients initially received a minimum of 3 days of empiric antibiotic therapy without resolution of fever. Within 24 hr of starting naproxen therapy, 10 patients' (83%) fever responded: Eight patients (80%) had a complete lysis of fever and two had partial lysis (20%). Temperature response was accompanied by subjective improvement in patient malaise and fatigue. Naproxen therapy was continued for 5-7 days in these patients, and chemotherapy was administered to those patients scheduled to receive it. Two patients did not respond to naproxen therapy in 24 hr; thus, it was stopped and the fever workup was continued. Of these two patients, one was eventually diagnosed with bacteremia after multiple negative blood cultures and initially no response to antibiotics. Naproxen is clinically useful in the palliation of fever-related symptoms in gynecologic oncology patients with suspected neoplastic fever. Naproxen may also allow the limitation of extensive fever workups and prolonged empiric antibiotic therapy in these patients, and prevent delays in systemic therapy or supportive care.

Original languageEnglish (US)
Pages (from-to)250-254
Number of pages5
JournalGynecologic Oncology
Volume56
Issue number2
DOIs
StatePublished - Feb 1995

Fingerprint

Naproxen
Fever
Neoplasms
Antipyretics
Anti-Bacterial Agents
Therapeutics
Temperature
Bacteremia
Infection
Fatigue
Pneumonia
Thorax

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

The Effect of Naproxen on Fever in Patients with Advanced Gynecologic Malignancies. / Economos, Katherine; Lucci, Joseph A.; Richardson, Barbara; Yazigi, Roberto; Miller, David Scott.

In: Gynecologic Oncology, Vol. 56, No. 2, 02.1995, p. 250-254.

Research output: Contribution to journalArticle

Economos, Katherine ; Lucci, Joseph A. ; Richardson, Barbara ; Yazigi, Roberto ; Miller, David Scott. / The Effect of Naproxen on Fever in Patients with Advanced Gynecologic Malignancies. In: Gynecologic Oncology. 1995 ; Vol. 56, No. 2. pp. 250-254.
@article{767c7365d98142d2a9f6449852b264be,
title = "The Effect of Naproxen on Fever in Patients with Advanced Gynecologic Malignancies",
abstract = "The antipyretic action of naproxen has been reported as sufficiently selective for neoplasm-related fever such that the use of this agent has been recommended to distinguish neoplastic from infectious fever. The antipyretic effect of naproxen was evaluated in gynecologic oncology patients with advanced pelvic malignancies and fever without obvious source of infection (suspected neoplastic fever). Naproxen (250 mg orally every 8 hr) was given to 12 patients with (i) a daily temperature greater than 38.3°C, (ii) fever for at least 3 days, (iii) no evidence of infection on physical exam, (iv) negative results of blood and urine cultures, and (v) a chest roentgenogram negative for pneumonia. Ten of the 12 patients initially received a minimum of 3 days of empiric antibiotic therapy without resolution of fever. Within 24 hr of starting naproxen therapy, 10 patients' (83{\%}) fever responded: Eight patients (80{\%}) had a complete lysis of fever and two had partial lysis (20{\%}). Temperature response was accompanied by subjective improvement in patient malaise and fatigue. Naproxen therapy was continued for 5-7 days in these patients, and chemotherapy was administered to those patients scheduled to receive it. Two patients did not respond to naproxen therapy in 24 hr; thus, it was stopped and the fever workup was continued. Of these two patients, one was eventually diagnosed with bacteremia after multiple negative blood cultures and initially no response to antibiotics. Naproxen is clinically useful in the palliation of fever-related symptoms in gynecologic oncology patients with suspected neoplastic fever. Naproxen may also allow the limitation of extensive fever workups and prolonged empiric antibiotic therapy in these patients, and prevent delays in systemic therapy or supportive care.",
author = "Katherine Economos and Lucci, {Joseph A.} and Barbara Richardson and Roberto Yazigi and Miller, {David Scott}",
year = "1995",
month = "2",
doi = "10.1006/gyno.1995.1041",
language = "English (US)",
volume = "56",
pages = "250--254",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The Effect of Naproxen on Fever in Patients with Advanced Gynecologic Malignancies

AU - Economos, Katherine

AU - Lucci, Joseph A.

AU - Richardson, Barbara

AU - Yazigi, Roberto

AU - Miller, David Scott

PY - 1995/2

Y1 - 1995/2

N2 - The antipyretic action of naproxen has been reported as sufficiently selective for neoplasm-related fever such that the use of this agent has been recommended to distinguish neoplastic from infectious fever. The antipyretic effect of naproxen was evaluated in gynecologic oncology patients with advanced pelvic malignancies and fever without obvious source of infection (suspected neoplastic fever). Naproxen (250 mg orally every 8 hr) was given to 12 patients with (i) a daily temperature greater than 38.3°C, (ii) fever for at least 3 days, (iii) no evidence of infection on physical exam, (iv) negative results of blood and urine cultures, and (v) a chest roentgenogram negative for pneumonia. Ten of the 12 patients initially received a minimum of 3 days of empiric antibiotic therapy without resolution of fever. Within 24 hr of starting naproxen therapy, 10 patients' (83%) fever responded: Eight patients (80%) had a complete lysis of fever and two had partial lysis (20%). Temperature response was accompanied by subjective improvement in patient malaise and fatigue. Naproxen therapy was continued for 5-7 days in these patients, and chemotherapy was administered to those patients scheduled to receive it. Two patients did not respond to naproxen therapy in 24 hr; thus, it was stopped and the fever workup was continued. Of these two patients, one was eventually diagnosed with bacteremia after multiple negative blood cultures and initially no response to antibiotics. Naproxen is clinically useful in the palliation of fever-related symptoms in gynecologic oncology patients with suspected neoplastic fever. Naproxen may also allow the limitation of extensive fever workups and prolonged empiric antibiotic therapy in these patients, and prevent delays in systemic therapy or supportive care.

AB - The antipyretic action of naproxen has been reported as sufficiently selective for neoplasm-related fever such that the use of this agent has been recommended to distinguish neoplastic from infectious fever. The antipyretic effect of naproxen was evaluated in gynecologic oncology patients with advanced pelvic malignancies and fever without obvious source of infection (suspected neoplastic fever). Naproxen (250 mg orally every 8 hr) was given to 12 patients with (i) a daily temperature greater than 38.3°C, (ii) fever for at least 3 days, (iii) no evidence of infection on physical exam, (iv) negative results of blood and urine cultures, and (v) a chest roentgenogram negative for pneumonia. Ten of the 12 patients initially received a minimum of 3 days of empiric antibiotic therapy without resolution of fever. Within 24 hr of starting naproxen therapy, 10 patients' (83%) fever responded: Eight patients (80%) had a complete lysis of fever and two had partial lysis (20%). Temperature response was accompanied by subjective improvement in patient malaise and fatigue. Naproxen therapy was continued for 5-7 days in these patients, and chemotherapy was administered to those patients scheduled to receive it. Two patients did not respond to naproxen therapy in 24 hr; thus, it was stopped and the fever workup was continued. Of these two patients, one was eventually diagnosed with bacteremia after multiple negative blood cultures and initially no response to antibiotics. Naproxen is clinically useful in the palliation of fever-related symptoms in gynecologic oncology patients with suspected neoplastic fever. Naproxen may also allow the limitation of extensive fever workups and prolonged empiric antibiotic therapy in these patients, and prevent delays in systemic therapy or supportive care.

UR - http://www.scopus.com/inward/record.url?scp=0028968442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028968442&partnerID=8YFLogxK

U2 - 10.1006/gyno.1995.1041

DO - 10.1006/gyno.1995.1041

M3 - Article

C2 - 7534741

AN - SCOPUS:0028968442

VL - 56

SP - 250

EP - 254

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -